Cellular control mechanisms that regulate pyruvate kinase M2 activity and promote cancer growth

Biomedical Research

Volumn 23, Issue SPEC. ISSUE, 2012, Pages 213-217

  Lyssiotis, Costas A ^a   Anastasiou, Dimitrios ^a   Locasale, Jason W ^a   Vander Heiden, Matthew G ^a,b   Christofk, Heather R ^c   Cantley, Lewis C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alternative splicing; Anabolic glucose metabolism; Glycolysis; Reactive oxygen species

Indexed keywords

CYSTEINE; PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

ALLOSTERISM; ALTERNATIVE RNA SPLICING; ANAEROBIC GLYCOLYSIS; ARTICLE; CANCER GROWTH; CELL FUNCTION; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION;

EID: 84857175147     PISSN: 0970938X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
2. Warburg O, Posener K, Negelein E. Ueber den Stoffwechsel der Tumoren. Biochem Z 1924; 152: 319-344.
3. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
4. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
5. Clower CV, et al. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A 2010; 107: 1894-1899.
6. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005; 15: 300-308.
7. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncog 1992; 3, 91-115.
8. Jurica MS, et al. The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure 1998; 6: 195-210.
9. Mazurek S, et al. Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells. Anticancer Res 2000; 20 5151-5154.
10. Gupta V, Bamezai RN. Human pyruvate kinase M2: a multifunctional protein. Protein Sci 2010; 19: 2031-2044.
11. Christofk HR, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-233.
12. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosinebinding protein. Nature 2008; 452: 181-186.
13. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010; 463: 364-368.
14. Anastasiou D, et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011; 334: 1278-1828.
15. Locasale JW, Cantley LC. Metabolic flux and the regulation of Mammalian cell growth. Cell Metab 2011; 14: 443-451.
16. Dombrauckas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005; 44: 9417-9429.
17. Kato H, Fukuda T, Parkison C, McPhie P, Cheng SY. Cytosolic thyroid hormone-binding protein is a monomer of pyruvate kinase. Proc Natl Acad Sci U S A 1989; 86: 7861-7865.
18. Marchut E, Guminska M, Kedryna T. The inhibitory effect of various fatty acids on aerobic glycolysis in Ehrlich ascites tumour cells. Acta Biochim Pol 1986; 33: 7-16.
19. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 2011; 43: 969-980.
20. Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 2009; 8: 308-320.
21. Maeba P, Sanwal BD. The regulation of pyruvate kinase of Escherichia coli by fructose diphosphate and adenylic acid. J Biol Chem 1968; 243: 448-450.
22. McDonagh B, Ogueta S, Lasarte G, Padilla CA, Barcena JA. Shotgun redox proteomics identifies specifically modified cysteines in key metabolic enzymes under oxidative stress in Saccharomyces cerevisiae. J Proteomics 2009; 72: 677-689.
23. Butterfield DA, Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J Alzheimers 2007; Dis 12: 61-72.
24. Cumming RC, et al. Protein disulfide bond formation in the cytoplasm during oxidative stress. J Biol Chem 2004; 279: 21749-21758.
25. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009; 8: 579-591.
26. Possemato R, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011; 476: 346-350.
27. Snell K, Natsumeda Y, Eble JN, Glover JL, Weber G. Enzymic imbalance in serine metabolism in human colon carcinoma and rat sarcoma. Br J Cancer 1988; 57: 87-90.
28. Locasale JW et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 2011; 43: 869-874.
29. Hitosugi T, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2009; 2: ra73.
30. Lv L, et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperonemediated autophagy and promotes tumor growth. Mol Cell 2011; 42: 719-730.
31. Locasale JW, Cantley LC, Vander Heiden MG. Cancer's insatiable appetite. Nat Biotechnol 2009; 27: 916-917.
32. Hardt PD, et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004; 91: 980-984.
33. Boxer MB, et al. Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J Med Chem 2010; 53: 1048-1055.